Patricia Cagnoli, MD
Rheumatology · Rochester Hills, MINPI 1457458713
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. GSK accounts for 80.8% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $34,614 and has fallen 80.7% since, to $6,689 in 2025. Among rheumatology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 460 payments — averaging $193.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$72K
- Johnson & Johnson$7K
- Lilly USA, LLC$4K
- AbbVie$920
- Amgen$854
- UCB, Inc.$668
- plus $3K from 22 others
Across 140 payments — averaging $3004.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$262K
- Eli Lilly$40K
- Pfizer$37K
- E.r. Squibb & Sons, L.L.C.$37K
- Sun Pharmaceutical Industries Inc.$30K
- Sanofi US Services Inc.$12K
- plus $1K from 1 others
What the payments were for
- Consulting fees$35,89640%
- Speaking & faculty fees$34,55039%
- Grants$9621%
- Travel & lodging$8,56010%
- Food & beverage$8,57210%
- Education$3080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 42 | $71,761 |
| Johnson & Johnson | 108 | $7,295 |
| Lilly USA, LLC | 9 | $4,011 |
| AbbVie | 42 | $920 |
| Amgen(2 entities) | 52 | $854 |
| UCB, Inc. | 29 | $668 |
| AstraZeneca(2 entities) | 22 | $562 |
| Novartis | 23 | $513 |
| Pfizer | 29 | $447 |
| E.r. Squibb & Sons, L.L.C. | 44 | $373 |
| ANI Pharmaceuticals, Inc. | 10 | $225 |
| Sanofi | 9 | $187 |
| Genentech USA, Inc. | 7 | $178 |
| Actelion Pharmaceuticals US, Inc. | 3 | $121 |
| Aurinia Pharma U.S., Inc. | 4 | $100 |
| Mallinckrodt Hospital Products Inc. | 4 | $96 |
| Sobi, Inc | 4 | $95 |
| Radius Health, Inc. | 4 | $88 |
| Fresenius Kabi USA, LLC | 3 | $82 |
| Hospira, Inc. | 2 | $56 |
| Fidia Pharma USA Inc. | 2 | $43 |
| Sandoz | 1 | $30 |
| Invivyd Inc | 2 | $29 |
| Octapharma USA, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Alvogen Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Organon | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$30,575
- Tremfya$5,304
- SIMPONI ARIA$522
- TALTZ$106
How this compares
$88,847 in reported general payments places this provider in the 90th percentile of 195 rheumatology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 43 | $287,304 |
| Enbrel SureclickEtanercept | 33 | $242,215 |
| Humira(Cf) PenAdalimumab | 20 | $224,809 |
| OtezlaApremilast | 28 | $134,877 |
| Humira(Cf)Adalimumab | 20 | $132,943 |
| EnbrelEtanercept | 15 | $110,840 |
| Enbrel MiniEtanercept | 14 | $105,572 |
| OrenciaAbatacept | 18 | $98,640 |
| RinvoqUpadacitinib | 13 | $91,995 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 11 | $80,892 |
| Orencia ClickjectAbatacept | 14 | $76,713 |
| BenlystaBelimumab | 15 | $68,082 |
| SaphneloAnifrolumab-Fnia | 12 | $61,839 |
| Hydroxychloroquine Sulfate | 211 | $13,058 |
| Buprenorphine | 27 | $12,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel | $854 | $245,71743 claims |
| AbbVieHumira(Cf), Rinvoq | $920 | $224,93833 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $373 | $98,64018 claims |
| GSKBenlysta | $71,761 | $68,08215 claims |
| AstraZenecaSaphnelo | $562 | $61,83912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 195 rheumatology providers in Michigan.
Other rheumatology in Rochester Hills
- Roman CzubatyjRochester Hills$764K
- John TowerRochester Hills$35K
- Dana RockwellRochester Hills$16K
- Josephine AlootRochester Hills$15K
- Phyllis BirkelRochester Hills$14K
- Amar MajjhooSaint Clair Shores$1.8M
- Andrew SulichSaint Clair Shores$1.7M
- Dinesh KhannaAnn Arbor$1.2M
- Delfin SantosRochester$242K
- Allan MortonWarren$229K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.